From: Analysis and enhancement of risk management for ethnic differences in antineoplastic drugs in Japan
Fix date of review report | Drug name | Drug category | Indication | Comparison between Japanese and non-Japanese population | Reference | |
---|---|---|---|---|---|---|
ADRsa | PKb | |||||
Feb 2010 | Panitumumab | Ab | Colorectal carcinoma | NO | Low | [16] |
May 2010 | Temsirolimus | TKI | Renal cell carcinoma | High | NM | [17] |
Jan 2011 | Eribulin mesilate | Ct | Breast cancer | High | ND | [18] |
Aug 2011 | Fulvestrant | Hr | Breast cancer | NO | High | [19] |
Mar 2012 | Crizotinib | TKI | NSCLC | High | High | [20] |
May 2012 | Axitinib | TKI | Renal cell carcinoma | NO | ND | [21] |
Aug 2012 | Pazopanib hydrochloride | TKI | Soft tissue cancer | NO | ND | [22] |
Mar 2013 | Regorafenib | TKI | Colorectal cancer | High | Low | [23] |
Apr 2013 | Pertuzumab | Ab | Breast cancer | High | ND | [24] |
Aug 2013 | Trastuzumab emtansin | Ab | Breast cancer | NO | ND | [25] |
Oct 2013 | Afatinib maleate | TKI | NSCLC | High | ND | [26] |
Jan 2014 | Enzalutamide | Hr | Prostate cancer | NO | ND | [27] |
Apr 2014 | Abiraterone acetate | Hr | Prostate cancer | High | ND | [28] |
Apr 2014 | Cabazitaxel acetate | Ct | Prostate cancer | High | ND | [13] |
Jun 2014 | Nivolumab | IO | Melanoma | High | ND | [29] |
Nov 2014 | Vemurafenib | TKI | Melanoma | High | ND | [30] |
Mar 2015 | Ramucirumab | Ab | Gastric cancer | High | ND | [31] |
May 2015 | Ipilimumab | IO | Melanoma | High | ND | [32] |
Jul 2015 | Vandetanib | TKI | Medullary thyroid cancer | High | High | [33] |
Aug 2015 | Trabectedin | Ct | Soft tissue tumor | High | NM | [34] |
Jan 2016 | Dabrafenib mesilate | TKI | Melanoma | High | NM | [35] |
Feb 2016 | Osimertinib mesilate | TKI | NSCLC | High | ND | [36] |
Mar 2016 | Ceritinib | TKI | NSCLC | High | ND | [37] |
Aug 2016 | Pembrolizumab | IO | Melanoma | NO | ND | [38] |
Jan 2017 | Afliberceot Beta | Ab | Colorectal cancer | High | NM | [39] |
Jul 2017 | Palbociclib | TKI | Breast cancer | High | ND | [40] |
Aug 2017 | Avelumab | IO | Merkel cell carcinoma | High | NM | [41] |
Oct 2017 | Atezolizumab | IO | NSCLC | NO | NM | [42] |
Nov 2017 | Olaparib | TKI | Ovarian cancer | High | ND | [43] |
Apr 2018 | Durvalumab | IO | NSCLC | High | Low | [44] |
Jul 2018 | Abemaciclib | TKI | Breast cancer | High | NM | [15] |
Aug 2018 | Lorlatinib | TKI | NSCLC | NO | ND | [45] |
Nov 2018 | Ebcorfenib/ Binimetinib | TKI | Melanoma | High | ND | |
Nov 2018 | Dacomitinib | TKI | NSCLC | NO | ND | [48] |
Jan 2019 | Apalutamide | Hr | Prostate cancer | NO | ND | [49] |
Apr 2019 | Necitumumab | Ab | Squamous NSCLC | High | ND | [50] |
May 2019 | Entrectinib | TKI | Solid tumors | High | ND | [51] |
Nov 2019 | Darolutamide | Hr | Prostate cancer | NO | ND | [52] |
Jan 2020 | Cabozantinib malate | TKI | Renal cell carcinoma | High | High | [53] |
Feb 2020 | Tepotinib hydrochloride hydrate | TKI | NSCLC | High | ND | [54] |
Feb 2020 | Irinotecan hydrochloride hydrate (liposome injection) | Ct | Pancreatic cancer | High | ND | [55] |
Feb 2020 | Trastuzumab deruxtecan | Ab | Breast cancer | High | NM | [56] |
May 2020 | Capmatinib hydrochloride hydrate | TKI | NSCLC | High | ND | [57] |
Aug 2020 | Niraparib tosilate hydrate | TKI | Ovarian cancer | High | ND | [58] |